ADIA, HarbourVest eye minor stake in Cohance

ADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent International. The investors plan to invest $350-400 million, valuing Cohance Lifesciences at $1.5 billion. Advent International currently owns a 76% stake in Suven Pharmaceuticals, which was merged with Cohance Lifesciences.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news